Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Cash from Investing Activities: 2019-2025

Historic Cash from Investing Activities for Allogene Therapeutics (ALLO) over the last 7 years, with Sep 2025 value amounting to $11.9 million.

  • Allogene Therapeutics' Cash from Investing Activities rose 115.71% to $11.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $116.9 million, marking a year-over-year increase of 32.49%. This contributed to the annual value of $75.7 million for FY2024, which is 53.65% down from last year.
  • Latest data reveals that Allogene Therapeutics reported Cash from Investing Activities of $11.9 million as of Q3 2025, which was down 72.77% from $43.8 million recorded in Q2 2025.
  • In the past 5 years, Allogene Therapeutics' Cash from Investing Activities ranged from a high of $112.9 million in Q1 2023 and a low of -$76.0 million during Q3 2024.
  • Over the past 3 years, Allogene Therapeutics' median Cash from Investing Activities value was $22.1 million (recorded in 2024), while the average stood at $27.4 million.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first surged by 745.02% in 2021, then crashed by 237.59% in 2023.
  • Over the past 5 years, Allogene Therapeutics' Cash from Investing Activities (Quarterly) stood at $29.2 million in 2021, then skyrocketed by 69.56% to $49.6 million in 2022, then soared by 36.02% to $67.5 million in 2023, then fell by 18.57% to $54.9 million in 2024, then spiked by 115.71% to $11.9 million in 2025.
  • Its Cash from Investing Activities stands at $11.9 million for Q3 2025, versus $43.8 million for Q2 2025 and $6.2 million for Q1 2025.